RT

Radiation-Tolerant DC-DC 50-Watt Power Converters Provide High-Reliability Solution for New Space Applications

Retrieved on: 
火曜日, 5月 7, 2024
QML, Radiation, Microchip Technology, LEO, Internet of things, Integrated circuit, MCHP, DC-DC, Family, Field-programmable gate array, EMI, TID, RT, Linear energy transfer, COTS

There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.

Key Points: 
  • There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.
  • The off-the-shelf LE50-28 family of power converters are designed to meet MIL-STD-461.
  • This series provides flexibility to parallel up to four power converters to reach 200-Watts.
  • Designed to serve 28V bus systems, the LE50-28 isolated DC-DC power converters can be integrated with Microchip’s PolarFire® FPGAs, microcontrollers and LX7720-RT motor control sensor for a complete electrical system solution.

Bayberry Town Center Breaks Ground

Retrieved on: 
火曜日, 5月 7, 2024
Men, Retail, Architecture, Office Products, Consumer, Home Goods, Residential Building & Real Estate, Commercial Building & Real Estate, Restaurant, Bar, Construction & Property, Supermarket, Women, Landscape, Food, Beverage, Weis Markets, Village, RT, Commercial property

Blenheim Group , the company that developed the 1,500-acre Village of Bayberry master-planned community just north of Middletown, Delaware, announced today it is starting site development activity at the highly-anticipated, 280,000-square-foot Bayberry Town Center.

Key Points: 
  • Blenheim Group , the company that developed the 1,500-acre Village of Bayberry master-planned community just north of Middletown, Delaware, announced today it is starting site development activity at the highly-anticipated, 280,000-square-foot Bayberry Town Center.
  • Bayberry Town Center will be anchored by a flagship, 64,000-square-foot Weis Markets and fuel facility.
  • When complete, Bayberry Town Center will also feature professional office space, two beautiful green spaces for community programming, 145 townhomes on the property, and internal street and trail connectivity with over 3,000 homes.
  • Bayberry Town Center has additional in-line and pad site restaurant and retail space available.

Together with Siemens Healthineers, Varian Showcases Commitment to Embracing Innovation and Enhancing Outcomes at ESTRO 2024

Retrieved on: 
木曜日, 5月 2, 2024
Cancer, ARIA, Radiation, EDGE, Siemens Healthineers, Medical examiner, Radiation therapy, Patient, Acquisition, PALO, RT, Standard of care, Health, Note, Medical imaging

With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.

Key Points: 
  • With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.
  • "As part of Siemens Healthineers, Varian is in a unique position to develop cutting-edge products and solutions that bridge the care gap globally," remarked Arthur Kaindl, Head of Varian.
  • Varian is committed to generating evidence that can help improve patient outcomes and expand access to care.
  • VARIAN, HYPERSIGHT, ETHOS, HALCYON, EDGE, TRUEBEAM, ARIA CORE, and IDENTIFY are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.

Together with Siemens Healthineers, Varian Showcases Commitment to Embracing Innovation and Enhancing Outcomes at ESTRO 2024

Retrieved on: 
木曜日, 5月 2, 2024
Cancer, ARIA, Radiation, EDGE, Siemens Healthineers, Medical examiner, Radiation therapy, Patient, Acquisition, PALO, RT, Standard of care, Health, Note, Medical imaging

With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.

Key Points: 
  • With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.
  • "As part of Siemens Healthineers, Varian is in a unique position to develop cutting-edge products and solutions that bridge the care gap globally," remarked Arthur Kaindl, Head of Varian.
  • Varian is committed to generating evidence that can help improve patient outcomes and expand access to care.
  • VARIAN, HYPERSIGHT, ETHOS, HALCYON, EDGE, TRUEBEAM, ARIA CORE, and IDENTIFY are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.

Dermatology Association of Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of Nonmelanoma Skin Cancer in Seven States

Retrieved on: 
月曜日, 4月 29, 2024
Education, Keloid, LCD, American Academy, Radiation, NCCN, Mohs surgery, Carcinoma, Policy, Skin, DART, National Comprehensive Cancer Network, American Academy of Dermatology, Recurrence, Research, SCC, Comment, Doctor of Philosophy, SRT, Radiation therapy, Documentation, NMSC, Patient, Treatment, Society, AAD, RT, BCC, ASTRO, Health insurance

The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.

Key Points: 
  • The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.
  • The DART filing noted, "In its current form, the LCD is fundamentally misdirected, misguided, and inappropriate.
  • It would altogether remove any semblance of patient choice or physician clinical decision making for patients who are diagnosed with NMSC.
  • At the outset, DART underscores that the proposed LCD was filed as a Medicare Part A policy.

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
水曜日, 4月 24, 2024
PFS, CMO, AMF, Cash, Pancreatic cancer, Research, Webcast, Lung, RT, AACR, Lung cancer, EIB, Conference call, Annual report, NBTXR3, ESMO, Conference, Janssen, NSCLC, Monroe Dunaway Anderson, Survival, Johnson & Johnson, Research and development, OS, Therapy, Neoplasm, Clinical trial, Cancer, Esophageal cancer, Immunotherapy, MD, Administration, University, URD, Patient, NANO, MD Anderson Cancer Center, Head, Bank statement, Growth, Pharmaceutical industry

PARIS and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2023, and announced the filing of its universal registration document (URD) for the financial year ended December 31, 2023 with the French financial market authority (Autorité des marchés financiers or AMF), as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • “2023 was an incredible year of progress for Nanobiotix and our NBTXR3 program.
  • “During 2023, we reported prolonged survival from Study 102 in head and neck cancer further reinforcing the design of our ongoing pivotal NANORAY-312 trial.
  • Cash and Cash Equivalents: As of December 31, 2023, Nanobiotix had €75.3 million in cash and cash equivalents, compared to €41.4 million as of December 31, 2022.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end results and an update on business activities before taking questions from participants.

GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress

Retrieved on: 
水曜日, 5月 1, 2024
Technology, Medical Devices, Health Technology, Software, Biotechnology, Radiology, Health, Artificial Intelligence, Oncology, Congress, Cancer, Brachy, BMJ, IRT, Spectronic, Electron, GE HealthCare, News, Hospital, Medical journal, Elekta, Research, Catalog, Workflow, Intelligence, Disease, Automation, Patient, Acquisition, RT, MRI, Diagnosis, Revolution, MIM, Medical imaging

Additionally, the company will showcase the newly acquired MIM Software portfolio, as well as other key innovations from GE HealthCare.

Key Points: 
  • Additionally, the company will showcase the newly acquired MIM Software portfolio, as well as other key innovations from GE HealthCare.
  • “At GE HealthCare, we are committed to advancing the frontiers of oncology treatment through AI-driven technologies that transform and optimize the care continuum,” said Dr. Taha Kass-Hout, chief technology and science officer of GE HealthCare.
  • At ESTRO 2024, GE HealthCare will also be showcasing the newly updated iRT platform, which was originally launched at ESTRO 2023.
  • To learn more about GE HealthCare’s latest innovations within oncology care, please visit the ESTRO 2024 Congress booth #220 in Glasgow from May 3-7 or visit the website here .

Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

Retrieved on: 
木曜日, 4月 25, 2024
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Research, Software, Hospitals, Genetics, Health Technology, Science, Data Management, Clinical Trials, Proton, Cancer, Lung cancer, Radiation, Chemoradiotherapy, SCLC, Vital signs, Collection, Carcinoma, Radiation therapy, Dermatitis, Esophagitis, NYPC, Fatigue, CRT, RT, Lung, Biomarker, NSCLC, Medical imaging

Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in collaboration with the New York Proton Center (NYPC), a leading institution in cancer care and research.

Key Points: 
  • Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in collaboration with the New York Proton Center (NYPC), a leading institution in cancer care and research.
  • The study, led by principal investigator Nitin Ohri, M.D., a professor in Radiation Oncology at the Montefiore Einstein Comprehensive Cancer Center, aims to demonstrate the feasibility of PGHD collection during proton beam radiotherapy for lung cancer.
  • “This pilot study represents a critical step in leveraging digital health technology to enhance cancer treatment outcomes,” said John Wagner, M.D., Ph.D., Chief Medical Officer, Koneksa.
  • Locally advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are typically treated with definitive thoracic radiotherapy (RT), often in the form of concurrent chemoradiotherapy (CRT).

ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting

Retrieved on: 
月曜日, 4月 22, 2024
Health, Stem Cells, Genetics, Health Technology, Pharmaceutical, Biotechnology, Abstract (summary), RNA, Cell, Engineering, Renegade, Gene, Society, Small RNA, Stem cell, RT, Annual general meeting, Therapy, Vaccine

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.
  • Improved retron-mediated target insertion through a combination of retron reverse transcriptase (RT) engineering, non-coding RNA (ncRNA) minimization, chemical modification, and homology-dependent repair manipulation.
  • Combination of retron system optimization and ncRNA engineering led to 2-fold higher 305 base pair insertion and ~40% editing efficiency in hematopoietic stem cells.
  • ASGCT Annual Meeting Presentation Details:

GE HealthCare’s MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

Retrieved on: 
月曜日, 4月 22, 2024
Technology, Surgery, Health Technology, Software, Biotechnology, Radiology, Health, Data Management, Oncology, Artificial Intelligence, Society, Cancer, IRT, Ecosystem, GE HealthCare, Maestro, Hospital, AI, Motivation, Molecular imaging, SNMMI, Artificial intelligence, ASCO, Automation, Patient, Acquisition, Intelligence, RT, Nuclear medicine, Radiation therapy, MIM, Medical imaging

“Our decision to join GE HealthCare was driven by a ‘shared vision of maximizing impact’ and our motivation for this collaboration with Elekta is no different,” explains Andy Nelson, CEO of MIM Software, GE HealthCare.

Key Points: 
  • “Our decision to join GE HealthCare was driven by a ‘shared vision of maximizing impact’ and our motivation for this collaboration with Elekta is no different,” explains Andy Nelson, CEO of MIM Software, GE HealthCare.
  • With the evolution of treatment planning software, we stand to make an impact on clinicians and patients worldwide.
  • “Today’s announcement is another demonstration of how MIM Software solutions enables advanced visualization and treatment planning offerings.
  • For more information on GE HealthCare and MIM Software’s radiation therapy solutions, please visit GEHealthCare.com and MIMSoftware.com .